Last reviewed · How we verify

NCT02988674: Adherence

A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

Completed Last updated 8 October 2020
What this trial tests

trial in Spondylarthritis in 139 participants. Completed in 16 October 2019.

Timeline
22 December 2016
Primary endpoint
16 October 2019
16 October 2019

Quick facts

Lead sponsorAbbVie
StatusCompleted
Study typeOBSERVATIONAL
Enrollment139
Start date22 December 2016
Primary completion16 October 2019
Estimated completion16 October 2019
Sites14 locations across Russia

Conditions studied

Sponsor

AbbVie — full company profile →

Who can join

Adults 18 to 99, any sex, with Spondylarthritis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in routine clinical settings in the Russian Federation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spondylarthritis

Currently open trials in the same condition.

Other AbbVie trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02988674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing